Medicalsystem Biotechnology Co., Ltd. (300439.SZ)
CNY 10.12
(0.8%)
CNY 10.12
(0.8%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 256.55 Million CNY | 29.23% |
| 2022 | 198.52 Million CNY | 10.61% |
| 2021 | 179.48 Million CNY | -40.07% |
| 2020 | 299.48 Million CNY | 151.94% |
| 2019 | -576.62 Million CNY | -339.09% |
| 2018 | 241.17 Million CNY | 4.99% |
| 2017 | 229.7 Million CNY | 31.64% |
| 2016 | 174.49 Million CNY | 8.2% |
| 2015 | 161.26 Million CNY | 17.13% |
| 2014 | 137.68 Million CNY | 32.99% |
| 2013 | 103.52 Million CNY | 12.86% |
| 2012 | 91.73 Million CNY | 72.02% |
| 2011 | 53.32 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 79.09 Million CNY | 197.42% |
| 2024 Q3 | 45.9 Million CNY | -53.81% |
| 2024 Q2 | 99.36 Million CNY | 25.63% |
| 2023 Q4 | 26.59 Million CNY | -51.73% |
| 2023 FY | 256.55 Million CNY | 29.23% |
| 2023 Q1 | 71.41 Million CNY | 1164.49% |
| 2023 Q3 | 55.09 Million CNY | -46.75% |
| 2023 Q2 | 103.45 Million CNY | 44.87% |
| 2022 FY | 198.52 Million CNY | 10.61% |
| 2022 Q2 | 76.98 Million CNY | 10.67% |
| 2022 Q4 | 5.64 Million CNY | -90.07% |
| 2022 Q1 | 69.56 Million CNY | 917.38% |
| 2022 Q3 | 56.89 Million CNY | -26.1% |
| 2021 Q3 | 39.6 Million CNY | -31.13% |
| 2021 FY | 179.48 Million CNY | -40.07% |
| 2021 Q1 | 75.54 Million CNY | 301202.76% |
| 2021 Q2 | 57.5 Million CNY | -23.88% |
| 2021 Q4 | 6.83 Million CNY | -82.74% |
| 2020 Q4 | 25.07 Thousand CNY | -99.97% |
| 2020 Q3 | 73.47 Million CNY | 21.8% |
| 2020 FY | 299.48 Million CNY | 151.94% |
| 2020 Q1 | 165.64 Million CNY | 121.64% |
| 2020 Q2 | 60.32 Million CNY | -63.58% |
| 2019 Q3 | 75.91 Million CNY | 31.35% |
| 2019 FY | -576.62 Million CNY | -339.09% |
| 2019 Q4 | -765.32 Million CNY | -1108.2% |
| 2019 Q2 | 57.79 Million CNY | -19.41% |
| 2019 Q1 | 71.71 Million CNY | 66.66% |
| 2018 Q1 | 71 Million CNY | 1.04% |
| 2018 Q4 | 43.02 Million CNY | -39.01% |
| 2018 Q2 | 63.32 Million CNY | -10.82% |
| 2018 Q3 | 70.54 Million CNY | 11.41% |
| 2018 FY | 241.17 Million CNY | 4.99% |
| 2017 Q3 | 66.25 Million CNY | 31.4% |
| 2017 FY | 229.7 Million CNY | 31.64% |
| 2017 Q1 | 44.14 Million CNY | 39.41% |
| 2017 Q2 | 50.42 Million CNY | 14.24% |
| 2017 Q4 | 70.27 Million CNY | 6.06% |
| 2016 Q3 | 57.32 Million CNY | 22.95% |
| 2016 FY | 174.49 Million CNY | 8.2% |
| 2016 Q2 | 46.62 Million CNY | 19.93% |
| 2016 Q1 | 38.87 Million CNY | -18.01% |
| 2016 Q4 | 31.66 Million CNY | -44.76% |
| 2015 Q1 | 33.08 Million CNY | -5.47% |
| 2015 Q4 | 47.41 Million CNY | 1.24% |
| 2015 Q3 | 46.83 Million CNY | 38.06% |
| 2015 Q2 | 33.92 Million CNY | 2.54% |
| 2015 FY | 161.26 Million CNY | 17.13% |
| 2014 FY | 137.68 Million CNY | 32.99% |
| 2014 Q3 | 46.68 Million CNY | 56.73% |
| 2014 Q4 | 34.99 Million CNY | -25.03% |
| 2014 Q1 | 26.21 Million CNY | 0.0% |
| 2014 Q2 | 29.78 Million CNY | 13.63% |
| 2013 FY | 103.52 Million CNY | 12.86% |
| 2012 FY | 91.73 Million CNY | 72.02% |
| 2011 FY | 53.32 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 307.46 Million CNY | 16.558% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.02 Billion CNY | 87.33% |
| Dirui Industrial Co.,Ltd. | 275.58 Million CNY | 6.908% |
| Beijing Strong Biotechnologies, Inc. | 523.74 Million CNY | 51.016% |
| Maccura Biotechnology Co.Ltd | 312.61 Million CNY | 17.935% |
| Guangzhou Wondfo Biotech Co.,Ltd | 487.62 Million CNY | 47.388% |
| Guangdong Hybribio Biotech Co.,Ltd. | 140.47 Million CNY | -82.635% |
| BGI Genomics Co., Ltd. | 92.9 Million CNY | -176.158% |
| Amoy Diagnostics Co., Ltd. | 261.48 Million CNY | 1.887% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | -141.59 Million CNY | 281.191% |